Review

Permissive role of endothelin receptors in tumor metastasis

Neveen Said a, Dan Theodorescu b,c,*

a Department of Urology, University of Virginia, USA
b Departments of Surgery and Pharmacology, University of Colorado, USA
c University of Colorado Comprehensive Cancer Center, USA

ARTICLE INFO

Article history:
Received 19 December 2011
Accepted 21 March 2012

Keywords:
Endothelin
Metastasis
Inflammation

ABSTRACT

Metastasis remains the major driver of mortality in patients with cancer. The multistep metastatic process requires the concerted actions of several genes and involves tumor cell invasion, epithelial mesenchymal transition (EMT), shedding from primary tumor, intravasation, arrest, extravasation and colonization at a preferential site. Understanding this complex process would provide the basis for the development of molecularly targeted therapeutics aimed at the tumor cell or its interaction with the host microenvironment. The neuropeptide hormones endothelins (specially, ET-1) have been correlated with invasiveness and metastasis of several cancers and high ET-1 levels are associated with decreased disease-specific survival. The mechanism(s) by which ET-1 promotes metastasis are being gradually unraveled. Through preferential binding to cognate receptors (ETAR or ETBR), ET-1 triggers autocrine and paracrine signaling cascades in tumor, immune and stromal cells, at both primary and distant sites, supporting cancer progression and metastasis. In this review, we will summarize the role of the ET axis in metastasis of different cancers and potential targeting of ET receptors in the therapeutic setting.

© 2012 Elsevier Inc.

Contents

Introduction ................................................................. 522
Ovarian cancer ............................................................ 523
Bladder cancer ............................................................. 523
Breast cancer ............................................................... 524
Prostate cancer ............................................................ 524
Colorectal cancer ........................................................ 525
Head and neck cancer ................................................... 525
Melanoma ................................................................. 525
The endothelin axis in bone metastasis ......................... 525
Conclusion ................................................................ 526
Conflict of interest statement ......................................... 526
Acknowledgments ........................................................ 526
Appendix A. Supplementary data ..................................... 526
References ................................................................. 526

Introduction

ET-1, an endothelial cell-derived vasoconstrictor peptide, is an important member of the endothelin axis with myriad developmental, physiological and pathological functions (Kedzierski and Yanagisawa, 2001; Herrmann et al., 2009, 2007; Hagemann et al., 2007). The "endothelin axis" consists of three similar small peptides, ET-1, ET-2 and ET-3, two G-protein-coupled receptors, ETAR and ETBR, and two membrane-bound proteases, the ET-converting enzymes, ECE-1 and ECE-2 (Kedzierski and Yanagisawa, 2001), that activate the secreted proforms of the peptide. ET-1 production is stimulated by a variety of cytokines and growth factors, hypoxia, and shear stress, while ETAR activation triggers signaling networks involved in cell proliferation, new vessel formation, invasion, inflammation and metastatic spread.
Ovarian cancer arises from the surface of the ovary. Hence cancer cells shed from the primary tumor can disseminate as floating single cells or spheroids in the peritoneal fluid and lead to implants on the mesothelial lining of the peritoneal cavity or deeply penetrate the omentum. In the ovarian cancer microenvironment, high ET-1 levels were detected in the peritoneal fluid in patients with malignant ascites (Bagnato et al., 2005). In vivo analysis of the ET-1 axis demonstrated a higher expression of ET-1 and ETar in primary and metastatic tumors than in normal ovarian tissues. Interestingly, ET-1-producing cells also expressed functional ETar, but not ETbr, indicating that in ovarian tumor cells, ET-1 likely acts as an autocrine factor selectively through the ETar (Bagnato et al., 2005).

In human ovarian tumors, ET-1 axis overexpression is associated with ascites formation, malignant progression, advanced tumor stage, and enhanced tumor angiogenesis (Bagnato et al., 1999, 2005). Here the ET-1/ETar axis drives multiple signaling networks involving epidermal growth factor receptors, integrins, Wnt, and MMPs (Bagnato and Rosano, 2007) that regulate cell survival, invasiveness, angiogenesis, vascular permeability and EMT (Rosano et al., 2010). ET-1 axis has been shown to be regulated by and induce activation of hypoxia-inducible factor 1α (HIF-1α) and EMT transcription factors as β-catenin/TCF, SNAIL and SLUG, suggesting that the ET-1 axis contributes to the complex cooperation between the intracellular signaling pathways and extracellular signals triggering EMT (Bagnato et al., 2005; Spinella et al., 2004a, 2004b, 2007; Rosano et al., 2001, 2007b, 2010; Bagnato and Rosano, 2007). Genome-wide expression profiling of ovarian carcinoma identified ETar as a key gene related to chemoresistance (Rosano et al., 2010). Interestingly, paclitaxel and platinum resistant ovarian cancer cells showed phenotypic changes consistent with EMT, providing strong evidence linking ETar signaling pathways to chemoresistance, EMT and stemness of ovarian cancer cells (Rosano et al., 2010).

In ovarian cancer, ETar has been recently shown to control T-cell homing to tumors and failure of immunotherapy as vaccine failure was associated with poor accumulation of T cells at the tumor site, in spite of detectable systemic antitumor immune response. ETar blockade with specific antagonist BQ-788 greatly enhanced the efficacy of
vaccines in both preventing recurrence and therapy directed at established tumors. BQ-788 did not increase systemic immune response to the vaccine in vivo, but rather greatly enhanced T-cell infiltration in tumors following vaccine (Kandalaft et al., 2009). Activation of a paracrine ET-1/ET_{AR} axis was also found between tumor cells and endothelial cells, whereby tumor cells overexpress and release ET-1 whereas the latter express ET_{AR}. This axis suppresses T-cell homing (even in the presence of tumor inflammation), and can be disrupted by ET_{AR} blockade, which in vivo markedly enhances tumor immune therapy (Kandalaft et al., 2009). ET_{AR} blockade is likely to have also direct antiangiogenic effects through suppression of endothelial nitric oxide. Interestingly, ET_{AR} upregulation predicts poor outcome in ovarian cancer (Buckanovich et al., 2008).

**Bladder cancer**

Gene expression data from several independent studies of human bladder cancer have revealed that ET1 and ET_{AR} were overexpressed in muscle invasive disease and that the degree of expression is associated with reduced patient survival (Said et al., 2011). This was confirmed at the protein level by ET-1 immunohistochemistry in human bladder cancer tissue microarrays (Said et al., 2011). Interestingly, ET-1 expression was positively correlated with the proinvasive and proinflammatory mediators IL-6, CCL2, COX2 as well as MMP2 and MMP9. However, an apparent paradox that has arisen in the field regarding the role of ET_{AR} in cancer is the finding that pharmacologic blockade of this receptor has minimal effect on primary tumor growth (Titus et al., 2005; Wulfing et al., 2005a, 2005b) yet affects experimental metastasis (Said et al., 2011; Titus et al., 2005) and that clinical trials with ET_{AR} inhibitors in patients with advanced cancers appear to have minimal effect (Bagnato et al., 2011; Nelson et al., 2008; Ohlmann et al., 2011; Clezardin, 2011; Nelson et al., 2011).

To decipher the role of ET-1/ET_{AR} axis in bladder cancer metastasis we used a comprehensive model whereby the endothelin axis, via ET_{AR}, was shown to drive bladder cancer lung colonization by regulating key factors in the microenvironment of disseminated tumor cells (Said et al., 2011). Using combined genetic and pharmacologic approaches in human bladder cancer cell lines in vitro, we reported the role of ET-1 in autocrine regulation of proliferation in bladder cancer cell lines and that ET-1 stimulates migration, invasion, and proteolytic activity of such cells through ET_{AR}. In vivo, using human and murine models of experimental and spontaneous lung metastasis, we showed that tumor ET-1 is a paracrine mediator of early metastatic colonization of the lung through triggering an early inflammatory response in the lung characterized by macrophage influx, and production of pro-inflammatory mediators MCP-1/CCL2, IL-6, and COX-2. Interestingly, the IL-6, MCP-1/CCL2, COX-2, and MMPs induced by ET-1 are also known to breach the lung vasculature and enable extravasation of cancer cells on dissemination of these cells to the lungs (Qian et al., 2009; Gupta and Massague, 2006; Gupta et al., 2007; Mantovani, 2009). This ET-1 or ET_{AR} mediated early inflammatory response led to subsequent development of macroscopic lung metastases. Interestingly, pharmacologic inhibition of ET_{AR} by ZD4054 prior to injection of tumor cells reduced the early inflammatory response and subsequent development of lung metastases. In contrast, when administration of ZD4054 was initiated after establishment of the early inflammatory response, the reduction in lung inflammation and clinical lung metastases was less dramatic. We also showed that the cellular effectors of this ET-1/ET_{AR} axis are likely macrophages since metastasis was suppressed by macrophage depletion by liposomal clodronate nanoparticles. Given this data we speculate that in clinical trials where pharmacologic inhibition of ET_{AR} did not affect primary tumor growth or established high-volume metastatic disease, these tumors were no longer dependent on macrophages for their maintenance or growth.

**Breast cancer**

Elevated expression of ET_{AR} in primary breast carcinoma is associated with reduced disease-free survival time (Wulfing et al., 2003). ET_{AR}-positive carcinomas frequently show staining for ET_{AR} in fibroblasts suggesting the existence of a paracrine axis since breast cancer cells express ET-1 (Wulfing et al., 2003; Kojima and Nihei, 1995). High ET-1/ET_{AR}-positive tumors were associated with clinicopathologic markers of aggressiveness and poor prognosis such as tumor size, poor differentiation, high grade, Her-2/neu overexpression, lymphovascular invasion, inflammation as well as with incidence of local recurrence or distant metastasis (Wulfing et al., 2003). The above findings suggested that ET-1 and ET_{AR} may be useful prognostic biomarkers in breast carcinomas and may help to identify patients who may benefit from adjuvant therapy (Wulfing et al., 2003). Mechanistic studies revealed that endothehlin (1 and 2) induce breast cancer cell invasiveness through HIF1α, inflammatory cytokines/chemokines, and MMPs (Grimsshaw et al., 2004; Grimsshaw, 2005; Yamashita et al., 1995; Wilson et al., 2006; Hagemann et al., 2005). ET-1 secretion in breast cancer cells is induced by EGF via EGFR and HER2 and involves MAPK-dependent signaling. In turn, an ET-1/ET_{AR}-dependent regulation of EGFR protein expression and phosphorylation (at Tyr845) was observed and conferred an additional anti-proliferative and anti-invasive effect to ET_{AR} blocker atrasentan, in trastuzumab treated cells (Fischgrabe et al., 2010). ET_{AR} antagonism also has additive antitumor activity in breast cancer cells treated with aromatase inhibitors in vitro and in vivo (Smollich et al., 2010). ET_{AR} blocker, ZD4045 was equipotent to aromatase inhibitors and in combination, exerted an additive effect on in vitro cells and in vivo in tumor xenografts (Smollich et al., 2010).

Recently, ET-1 was found to mediate the invasive properties of triple-negative breast cancer (TNBC) (Ha et al., 2011) as a downstream effector of lactoferrin (Lf) which efficiently downregulates levels of ER-alpha, PR, and HER-2 in a proteasome-dependent manner (Ha et al., 2011) with subsequent loss of responsiveness of breast cancer cells to ER- or HER-2-targeted therapies. Lactoferrin-induced increased invasion of breast cancer cells was mediated via transcriptional stimulation of ET-1 and was effectively blocked by antagonists of the ET-1 receptor. Co-overexpression of lactoferrin and ET-1 in tumors as well as elevated circulating levels was observed in serum from TNBC as compared with samples from ER-, PR-, and HER-2-positive breast tumors. Thus targeting Lf-ET-1 axis in TNBC represents a new promising approach (Ha et al., 2011).

**Prostate cancer**

ET-1 plasma concentrations are elevated in men with metastatic and hormone refractory prostate cancer compared to those with locally confined disease or healthy control (Nelson et al., 1995). Immunohistochemistry revealed that primary prostate cancers and prostate cancer bone metastases were usually positive for ET-1 expression (Nelson et al., 1995, 1996). Prostate cancers express higher ET-1 and ET_{AR} but less ET_{AR} than normal prostate tissue (Nelson et al., 1996). The in vitro mitogenic effect of exogenous ET-1 on prostate cancer cell lines is modest, but it enhances the effects of a variety of growth factors such as basic fibroblast growth factor b (bFGF), insulin-like growth factor (IGF), and platelet-derived growth factor (PDGF) (Nelson et al., 2003), and in conjunction with VEGF, plays a major role in tumor angiogenesis. ET-1, through ET_{AR}, transactivates EGFR (Konetny and Nelson, 2001), a finding that was verified in a recent study by Wang et al. (2011). The ET-1/ET_{AR}-EGFR pathway was shown to activate the PI3K/AKT pathway, which is known to play an important role in prostate cancer progression (Nelson et al., 2003). ET-1 also activates focal adhesion kinase (FAK) and elevates intracellular calcium in several prostate cancer cell lines (Dawson et al., 2004, 2006; Nelson et al., 2003). ET-1 expression is also associated with the transition from androgen-dependent to androgen-independent
when given at the time of, but not after, tumor cell inoculation suggest-

Colorectal cancer

Preoperative plasma big ET-1 concentration is a predictor of over-

sensitivity to chemotherapy (Mai et al., 2006). The

ETAR was overexpressed in 74% of NPC and its expression was found

significantly reduced in micrometastasis specimens (Spinella et al., 2007; Jamal and Schneider, 2002). In addition, ET-1/

ETAR upregulates melanoma cell adhesion molecule (MCAM), a marker of melanoma aggressiveness and metastasis, in primary and metastatic melanoma cell lines (Mangahas et al., 2004). In melanoma cell lines, ET increases HIF-1α with subsequent upregulation of vascular endothelial growth factor (VEGF), COX-1/COX-2 expression and activity and PGE2 production in normoxic and hypoxic conditions (Spinella et al., 2007). COX-1/COX-2 inhibitors blocked ET-induced PGE2 and VEGF secretion, MMP activation and cell invasion, indicating that both enzymes function as downstream mediators of ET-1 induced invasive properties. In melanoma xenografts, ETAR blockade suppressed HIF-1α accumulation, tumor growth, neovascularization, VEGF expression and MMP-2 (Spinella et al., 2007). Moreover, ET-1 and -3 induced secretion of pro-

metastatic CXC chemokines (Mangahas et al., 2005) further implicating the proinflammatory properties of ET-1 in melanoma invasiveness and metastasis.

The endothelin axis in bone metastasis

In addition to the effects of ET-1 on tumor growth and invasiveness, the paracrine effects of tumor-produced ET-1 on bone cells may create a fertile growth environment for tumor cells in bone. In the bone micro-

environment, tumor-derived ET-1 stimulates mitogenesis in osteo-
blasts, which express both ETAR and ETBR, and it decreases osteoclast activity and motility (Nelson et al., 2003), and therefore is involved in the formation of osteoblastic lesions that are frequently observed in patients with metastatic prostate cancer and, to a lesser extent, in metastatic breast cancer (Nelson et al., 2003). In preclinical models, osteoblastic bone metastases elicited by human and murine breast cancer cell lines were inhibited by ETAR antagonist atrasentan (Guise et al., 2003; Yin et al., 2003) and the mixed (ETAR and ETBR) inhibitor bosentan (Dreau et al., 2006). The effect of the ET1 receptor-selective antagonists ABT-627 to block ET-1-stimulated osteoblast proliferation and new bone formation was specific because it did not block FGF-2-stimulated new bone formation (Guise et al., 2003). In prostate cancer, ET-1 production was down-regulated by androgens and up-regulated by the bone-associated factors transforming growth factor β (TGFβ), EGF, IL-1-β, IL-1-α, and TNF-α (Le Brun et al., 1999). Co-cultures of prostate cancer and bone have demonstrated that ET-1 production is increased by prostate cancer cells in contact with bone (Chiao et al., 2000). These effects are mediated via ETαR (Nelson et al., 1995, 1996).

Conclusion

The ET axis is deeply implicated in the malignant process and tumor progression in several tumor types. In addition components of this axis have potential as prognostic and predictive biomarkers. The pro-

metastatic effect of ET/ETRs in most cancers involves paracrine effects regulating tumor-stromal interactions and involving pro-inflammatory cytokines/chemokines, COX2 and the matrix metalloproteinase. Indeed the identification of endothelin and biomarkers associated with it (Said et al., 2011) in primary tumors begets the design of clinical trials with endothelin axis inhibitors either after radical surgery or in combi-
nation with standard of care chemo or radiotherapy to hamper metastatic seeding. Interestingly, despite significant evidence for a role in cancer, prostate cancer has been the only human tumor where significant clinical
studies have been undertaken to explore the benefits of interrupting the ET axis.

Conflict of interest statement

The authors declare that there are no conflicts of interest.

Acknowledgments

This study was supported by NIH grant CA143971 to D. Theodorescu.

Appendix A. Supplementary data

Supplementary data to this article can be found online at doi: 10.116/j.lfs.2012.03.040.

References


